The world’s first vaccine for respiratory syncytial virus (RSV) has just been approved by the Food and Drug Administration. The vaccine is called Arexvy and was developed by GlaxoSmithKline. It will be approved to prevent lower respiratory tract disease from the infection in those over age 60.
